Publications in collaboration with researchers from Humanitas Research Hospital (15)

2026

  1. A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)

    Future Oncology, Vol. 22, Núm. 10, pp. 1135-1152

  2. CheckMate-9DW 4-year follow-up: Overall survival by depth of response and outcomes in long-term survivors.

    Journal of Clinical Oncology, Vol. 44, pp. 4104-4104

  3. Correction to: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR (European Radiology, (2025), 10.1007/s00330-025-11699-7)

    European Radiology

  4. Harmonizing Definitions and Perspectives in Extreme Liver Surgery: A Delphi Experts Consensus

    Annals of surgery, Vol. 283, Núm. 3, pp. 469-478

  5. Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR

    European Radiology, Vol. 36, Núm. 1, pp. 597-606

  6. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)

    Future Oncology, Vol. 22, Núm. 12, pp. 1359-1372

  7. The hepatocellular carcinoma wish list: Five aspirations for future care

    Journal of Hepatology

  8. Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement

    Nature Reviews Clinical Oncology, Vol. 23, Núm. 8, pp. 619-647

  9. Utility of the Iwate Difficulty Scoring System for the Stratification of Laparoscopic Right Hepatectomies: An International Multicenter Study

    Journal of Hepato-Biliary-Pancreatic Sciences

2025

  1. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

    Liver Cancer

  2. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

    Journal of Hepatology, Vol. 83, Núm. 4, pp. 899-908

2024

  1. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457

  2. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

  3. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome

    JHEP Reports, Vol. 6, Núm. 7

  4. Tailoring the Use of Central Pancreatectomy Through Prediction Models for Major Morbidity and Postoperative Diabetes: International Retrospective Multicenter Study

    Annals of Surgery, Vol. 280, Núm. 6, pp. 993-998